GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.
Target Company Name:
Country:
Advisory:
Sector:
Partner:
Country:
Advisory:
Sector:
Partner:
GrandPharm obtained the right to develop and commercialize BRM421 in greater China. At the same time, GrandPharm subscribed for a small amount of equity of Brimbiotech
BRM421
Grandpharma
GrandPharm obtained the right to commercialize BRM421,a new drug for dry eye syndrome, in mainland China, HK and Macau.
Advisor to the seller
